Incyte
INCYApprovedFounded in 2002 and headquartered in Wilmington, Delaware, Incyte has evolved from a small team of scientists into a leading global biopharmaceutical company with three core franchises. The company maintains a robust pipeline with ongoing clinical trials in dozens of disease areas and has been recognized as a top employer by Science Magazine for eight consecutive years. With over 1,000 research and clinical development employees, Incyte continues to advance breakthrough treatments under their mission to 'Solve On' for patients worldwide.
INCY · Stock Price
Historical price data
AI Company Overview
Founded in 2002 and headquartered in Wilmington, Delaware, Incyte has evolved from a small team of scientists into a leading global biopharmaceutical company with three core franchises. The company maintains a robust pipeline with ongoing clinical trials in dozens of disease areas and has been recognized as a top employer by Science Magazine for eight consecutive years. With over 1,000 research and clinical development employees, Incyte continues to advance breakthrough treatments under their mission to 'Solve On' for patients worldwide.
Technology Platform
Global biopharmaceutical company focused on discovery, development and commercialization of novel medicines targeting specific molecular pathways across hematology, oncology, and inflammation & autoimmunity therapeutic areas.
Pipeline
402| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ruxolitinib cream | Atopic Dermatitis | Approved | |
| Povorcitinib + Placebo | Hidradenitis Suppurativa (HS) | Phase 3 | |
| Ruxolitinib Cream + Vehicle Cream | Hidradenitis Suppurativa | Phase 3 | |
| Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + ... | Graft-versus-host Disease (GVHD) | Phase 3 | |
| Tafasitamab + Lenalidomide | Large B-Cell Lymphoma | Phase 3 |
Funding History
3FDA Approved Drugs
6Opportunities
Risk Factors
Competitive Landscape
Competes with major pharmaceutical companies including Novartis, Bristol Myers Squibb, Roche, and AbbVie across hematology and oncology markets. Differentiated through focused approach to rare diseases, specialized molecular targets, and proven track record of successful drug approvals and commercial execution.